- Topline supports moving to Phase 3 trial and shows potential to develop GV1001 as the world's first PSP treatment PSP is a degenerative disease that, like Parkinson's disease, causes symptoms such ...

BARCELONA, Spain--(BUSINESS WIRE)--Ferrer, a B Corp-certified international pharmaceutical company, has announced the dosing of the first participant in the Phase II clinical trial, PROSPER. The study ...

The inability to identify PSP has hampered the development of new treatments, according to co-senior author Adam Boxer, MD, PhD, endowed professor in memory and aging at the UCSF Department of ...

Progressive supranuclear palsy (PSP), a mysterious and deadly neurological disorder, usually goes undiagnosed until after a patient dies and an autopsy is performed. But now, UC San Francisco ...

Drawing from UK Biobank data, Mass General Brigham researchers have uncovered specific health factors linked to higher or lower risk of developing progressive supranuclear palsy (PSP), a rare but ...